	41							
1	KAMALA D. HARRIS							
2	Attorney General of California JAMES M. LEDAKIS							
3	Supervising Deputy Attorney General NICOLE R. TRAMA							
4	Deputy Attorney General State Bar No. 263607							
5	110 West "A" Street, Suite 1100 San Diego, CA 92101							
6	P.O. Box 85266 San Diego, CA 92186-5266							
7	Telephone: (619) 645-2143 Facsimile: (619) 645-2061 Attorneys for Complainant							
8		THE THE						
9	BEFORE THE BOARD OF PHARMACY							
10	DEPARTMENT OF CONSUMER AFFAIRS STATE OF CALIFORNIA							
11								
12	In the Matter of the Accusation Against:	Case No. 5059						
13	D & R PHARMACY, INC.,	ACCHGATION						
14	DBA PICO UNION PHARMACY 1273 S. Union Ave Los Angeles, CA 90015	ACCUSATION						
15 16	Pharmacy Permit No. PHY 45340							
	and							
17	DANA MADIEVSKY 11357 Dona Lisa Drive Studio City, CA 91604							
19	Pharmacist License No. RPH 48684							
20	Respondents.							
21								
22								
23	Complainant alleges:							
24	PARTIES							
25	Virginia Herold (Complainant) bring	s this Accusation solely in her official capacity						
26	as the Executive Officer of the Board of Pharmacy, Department of Consumer Affairs.							
27	2. On or about August 28, 2001, the Board of Pharmacy issued Permit Number 45340 to							
28	D & R Pharmacy, Inc., dba Pico Union Pharmacy (Respondents). The Permit was in full force							

and effect at all times relevant to the charges brought herein and will expire on August 1, 2014, unless renewed.

3. On or about April 23, 1996, the Board of Pharmacy issued Pharmacist License No. RPH 48684 to Dana Madievsky (Respondent). The Pharmacist License was in full force and effect at all times relevant to the charges brought herein and will expire on July 31, 2015, unless renewed.

JURISDICTION

- 4. This Accusation is brought before the Board of Pharmacy (Board), Department of Consumer Affairs, under the authority of the following laws. All section references are to the Business and Professions Code unless otherwise indicated.
- 5. Section 4011 of the Code provides that the Board shall administer and enforce both the Pharmacy Law [Bus. & Prof. Code, § 4000 et seq.] and the Uniform Controlled Substances Act [Health & Safety Code, § 11000 et seq.].
- 6. Section 4300(a) of the Code provides that every license issued by the Board may be suspended or revoked.
 - 7. Section 4300.1 of the Code states:

The expiration, cancellation, forfeiture, or suspension of a board-issued license by operation of law or by order or decision of the board or a court of law, the placement of a license on a retired status, or the voluntary surrender of a license by a licensee shall not deprive the board of jurisdiction to commence or proceed with any investigation of, or action or disciplinary proceeding against, the licensee or to render a decision suspending or revoking the license.

STATUTORY PROVISIONS

8. Section 4022 of the Code states:

"Dangerous drug" or "dangerous device" means any drug or device unsafe for self-use in humans or animals, and includes the following:

- (a) Any drug that bears the legend: "Caution: federal law prohibits dispensing without prescription," "Rx only," or words of similar import.
- (b) Any device that bears the statement: "Caution: federal law restricts this device to sale by or on the order of a _____," "Rx only," or words of similar import,

COST RECOVERY

13. Section 125.3 of the Code provides, in pertinent part, that the Board may request the administrative law judge to direct a licentiate found to have committed a violation or violations of the licensing act to pay a sum not to exceed the reasonable costs of the investigation and enforcement of the case, with failure of the licentiate to comply subjecting the license to not being renewed or reinstated. If a case settles, recovery of investigation and enforcement costs may be included in a stipulated settlement.

DRUGS

- 14. Amoxicillin, is a dangerous drug pursuant to Business and Professions Code section 4022.
- 15. Bactrim DS, a brand name for trimethoprim/sulfam ethoxazole, is a dangerous drug pursuant to Business and Professions Code section 4022.
- 16. Keflex, a brand name for cephalexin, is a dangerous drug pursuant to Business and Professions Code section 4022.
- 17. Lortab, a brand name for hydrocodone, is a Schedule III controlled substance pursuant to Health and Safety Code section 11056, subdivision (e), and a dangerous drug pursuant to Business and Professions Code section 4022.
- 18. Norco, a brand name for acetaminophen and hydrocodone bitartrate, is a Schedule III controlled substance pursuant to Health and Safety Code section 11056, subdivision (e), and a dangerous drug pursuant to Business and Professions Code section 4022.
- 19. Phenergan/Codeine, the brand name for Promethazine with Codeine Syrup is a Schedule V controlled substance under Health and Safety Code section 11058 and is a dangerous drug pursuant to Business and Professions Code section 4022.

FACTUAL ALLEGATIONS

20. At all times mentioned herein and since August 28, 2001, Dana Madievsky (Respondent) has been the President and Pharmacist-in-Charge (PIC) of D & R Pharmacy, Inc., dba Pico Union Pharmacy (Respondent) located in Los Angeles, California.

- 21. From August 1, 2010 to June 10, 2011, Respondents dispensed 596 fraudulent prescriptions to patients allegedly written by Dr. D.B. Of the 596 fraudulent prescriptions, 16 prescriptions were for hydrodcodone products, 290 prescriptions were for Phenergan with Codeine, and 290 prescriptions were for antibiotics (Keflex 500 mg, Bactrim DS, and Amoxicillin 500 mg). All of the hydrocodone prescriptions (Lortab 10/500 mg and Norco 10/325 mg) were dispensed with the same directions to take one tablet every six to eight hours and in the same total quantity of one hundred tablets. All of the 290 prescriptions for Phenergan with Codeine showed the same directions (take 1 teaspoon every six to eight hours) and the same total quantity (1 pint) and were prescribed on the same prescription document as the antibiotic. All of the prescriptions for antibiotics showed the same total quantity (10 capsules).
- 22. Dr. D.B. did not write or authorize any of the fraudulent prescriptions. None of the patients who were dispensed fraudulent prescriptions were patients of Dr. D.B. or were patients at the clinic where Dr. D.B. worked. Respondents never contacted Dr. D.B. or the clinic to verify the fraudulent prescriptions prior to dispensing the drugs to patients.
- 23. During the Board of Pharmacy's investigation, copies of the original fraudulent prescriptions were obtained from Respondents. The majority of the prescriptions were noted by Respondents as "verified with Michelle and Akisha" on the back of the prescription documents. However, nobody by the name "Michelle" or "Akisha" were employed by Dr. D.B. or the clinic where Dr. D.B. worked. Dr. D.B. confirmed that the clinic would not verify these prescriptions because the clinic never saw those patients.
- 24. Respondents were also unable to produce the original prescriptions for the following six prescriptions that were dispensed: RX No. 1559731 for Bactrim dispensed to D.J.; RX No. 1559732 for Phenergan with Codeine dispensed to D.J.; RX No. 1566999 for Phenergan with Codeine dispensed to B.A.; RX No. 1567000 for Bactrim dispensed to B.A.; RX No. 1555690 for Phenergan with Codeine dispensed to S.M.; and RX No. 1555691 for Bactrim dispensed to S.M.

2

3 4

5

7

8

9

10 11

12

13

14 15

16

17

18

19 20

21

22

2324

25

26

27

28 | LA2014511025/70874826,doc

DATED:

FIRST CAUSE FOR DISCIPLINE

(Dispensing Erroneous, Irregular, Uncertain, or Altered Prescriptions)

25. Respondents are subject to disciplinary action for unprofessional conduct under Code section 4301, subdivision (o), for violation of California Code of Regulations section 1761(a) for dispensing prescriptions which contained significant errors, omissions, irregularities, uncertainties, ambiguities or alterations, and failing to verify the prescriptions with the prescriber, as set forth in paragraphs 20 through 24, which are incorporated herein by reference.

SECOND CAUSE FOR DISCIPLINE

(Failure to Maintain Prescription Records)

26. Respondents are subject to disciplinary action for unprofessional conduct under Code section 4301, subdivision (o), for violation of Code section 4333 failing to maintain prescription records, as set forth in paragraphs 20 through 24, which are incorporated herein by reference.

PRAYER

WHEREFORE, Complainant requests that a hearing be held on the matters herein alleged, and that following the hearing, the Board of Pharmacy issue a decision:

- 1. Revoking or suspending Permit Number 45340, issued to D & R Pharmacy, Inc., dba Pico Union Pharmacy;
- 2. Revoking or suspending Pharmacist License Number RPH 48684, issued to Dana Madievsky;
- 3. Ordering Respondents to pay the Board of Pharmacy the reasonable costs of the investigation and enforcement of this case, pursuant to Business and Professions Code section 125.3:

4.	Taking a	ich other	and further	action ac	hamaah	nececcard	and	nroner	
4.	raking st	ton omer s	and further	action as	deemed	Hecessai y	anu	propos	f.

8/16/14

VIRGINIA HEROLD

Executive Officer Board of Pharmacy

Department of Consumer Affairs

State of California Complainant

6